Kowalsky Matthew Paul
SEC CIK 1705824 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | CLO | 1,318 | — | — | 2 | 2026-02-12 | 2026-02-12 |
Most active insiders at ENTA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Luly Jay R. | Pres, CEO, Dir | — | $67.5K |
| 2 | Or Yat Sun | CSO | — | $34.0K |
| 3 | Kieffer Tara Lynn | Chief Product Strategy Off | — | $30.0K |
| 4 | Luu Brendan | Chief Business Off | — | $19.8K |
| 5 | Trout Harry R. III | See Remarks | — | $13.0K |
| 6 | Rottinghaus Scott T. | Chief Medical Off | — | $11.4K |
| 7 | Capps Kathleen S. | See Remarks | — | $7,486 |
| 8 | Kowalsky Matthew Paul | CLO | — | — |
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-13 | 2026-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kowalsky Matthew Paul | CLO | A - Grant | $0.00 | +5,493 | 1,318 | New | $0 |
| 2026-02-13 | 2026-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kowalsky Matthew Paul | CLO | F - Tax | $14.25 | -1,902 | 3,591 | -35% | -$27.1K |
Purchase Sale Sale after option exercise All abbreviations